8-K: Korro Bio Reports Full Year 2024 Financial Results and Provides Business Updates

Korro Bio announces full year 2024 financial results, highlights clinical trial progress, and provides business updates, including a strong cash position and upcoming milestones.

Summary

• Korro Bio reported its full-year 2024 financial results and provided business updates on March 18, 2025.
• The company completed dosing of the first two cohorts in the Phase 1/2a REWRITE clinical study of KRRO-110 for Alpha-1 Antitrypsin Deficiency (AATD), with an interim readout expected in the second half of 2025.
• The FDA granted Orphan Drug Designation to KRRO-110 for the treatment of AATD.
• Korro is executing a 3-2-1 strategy through the end of 2027, aiming to establish three clinical-stage development programs targeting two tissue types with a single RNA-editing platform.
• The company expects to announce its second development candidate in 2025.
• Korro strengthened its leadership team with the formation of a Clinical Advisory Board and key additions to the board and management team.
• The company ended 2024 with $163.1 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into the second half of 2026.
• Collaboration revenue for the year ended December 31, 2024, was $2.3 million, compared to none in the previous year, due to the Novo Nordisk partnership.
• The net loss for 2024 was $83.6 million, compared to $81.2 million in 2023.
• Research and Development expenses were $63.6 million for the year ended December 31, 2024, as compared to $57.2 million for the year ended December 31, 2023.
• General and Administration expenses were $30.5 million for the year ended December 31, 2024, as compared to $27.3 million for the year ended December 31, 2023.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the strong cash position, clinical trial progress, and collaboration with Novo Nordisk. However, the net loss and increased expenses temper the overall outlook.

Positives

• Korro Bio has a strong cash position of $163.1 million, providing a runway into the second half of 2026.
• The company's collaboration with Novo Nordisk generated $2.3 million in revenue for 2024.
• KRRO-110 received Orphan Drug Designation from the FDA, offering development incentives.
• The company is progressing its 3-2-1 strategy, aiming to have three clinical-stage programs by the end of 2027.
• Korro has strengthened its leadership team with key appointments.

Negatives

• Korro Bio reported a net loss of $83.6 million for the year ended December 31, 2024.
• Research and Development expenses increased to $63.6 million for the year ended December 31, 2024.
• General and Administration expenses increased to $30.5 million for the year ended December 31, 2024.

Risks

• Clinical trial outcomes are uncertain, and the interim readout for KRRO-110 in the second half of 2025 may not be positive.
• Regulatory approvals for KRRO-110 and other pipeline candidates are not guaranteed.
• The company's cash runway is projected to last into the second half of 2026, but unforeseen expenses or delays could require additional funding.
• General economic conditions and geopolitical uncertainty could impact the company's operations and financial performance.

Future Outlook

Korro Bio anticipates an interim readout from the Phase 1/2a REWRITE clinical study of KRRO-110 in the second half of 2025 and expects to nominate a development candidate for its rare metabolic disorder program by the end of 2025. The company expects its cash to fund operations into the second half of 2026.

Management Comments

• Ram Aiyar, PhD, CEO and President of Korro, stated that the company executed on its key objectives in 2024 by initiating the Phase 1/2a REWRITE clinical study of KRRO-110 for AATD, announcing a collaboration with Novo Nordisk, and advancing multiple product candidates in the pipeline.
• He also mentioned that KRRO-110 has best-in-class potential based on preclinical data and expressed excitement about potentially demonstrating this in PiZZ patients in the second half of 2025 with the interim data readout of REWRITE.
• Aiyar highlighted the company's strategy of taking three development candidates in two tissue types with a single RNA-editing platform in the clinic by the end of 2027.

Industry Context

Korro Bio's focus on RNA editing places it within a growing field of genetic medicine companies. The collaboration with Novo Nordisk highlights the increasing interest from larger pharmaceutical companies in leveraging RNA editing technologies for prevalent diseases like cardiometabolic disorders. The Orphan Drug Designation for KRRO-110 underscores the importance of addressing rare diseases with innovative therapies.

Comparison to Industry Standards

• Korro Bio's cash runway into the second half of 2026 is comparable to other clinical-stage biopharmaceutical companies of similar size and development stage.
• The company's R&D expenses are in line with industry averages for companies advancing novel therapeutic modalities like RNA editing.
• The collaboration with Novo Nordisk is a positive sign, as partnerships with larger pharmaceutical companies are often seen as validation of a company's technology and potential.
• Companies like Wave Life Sciences and Dicerna Pharmaceuticals (acquired by Novo Nordisk) also focus on RNA-based therapies, but Korro's RNA editing approach differentiates it from traditional RNA interference or antisense oligonucleotide approaches.

Stakeholder Impact

• Shareholders: The financial results and business updates provide information for investors to assess the company's progress and potential.
• Employees: The company's continued development and strong cash position provide job security and opportunities for growth.
• Patients: The development of KRRO-110 and other pipeline candidates offers potential new treatment options for rare and prevalent diseases.
• Partners: The collaboration with Novo Nordisk benefits both companies by leveraging their respective expertise and resources.

Next Steps

• Korro Bio will continue to enroll patients in the Phase 1/2a REWRITE clinical study of KRRO-110.
• The company expects an interim readout from the REWRITE study in the second half of 2025.
• Korro Bio plans to nominate a development candidate for its rare metabolic disorder program by the end of 2025.
• The company will continue to progress its partnership with Novo Nordisk in cardiometabolic diseases.

Key Dates